- Home
- COLL vs HTO Comparison
COLL vs HTO Comparison
Compare COLL & HTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COLL | HTO |
|---|---|---|
| Founded | 2002 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Supply |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | COLL | HTO |
|---|---|---|
| Price | $47.02 | $46.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | $47.50 | ★ $58.00 |
| AVG Volume (30 Days) | ★ 550.1K | 405.7K |
| Earning Date | 11-06-2025 | 10-27-2025 |
| Dividend Yield | N/A | ★ 3.61% |
| EPS Growth | N/A | ★ 14.49 |
| EPS | 1.63 | ★ 3.17 |
| Revenue | $757,067,000.00 | ★ $804,224,000.00 |
| Revenue This Year | $26.35 | $9.75 |
| Revenue Next Year | $3.67 | $8.19 |
| P/E Ratio | $29.21 | ★ $14.66 |
| Revenue Growth | ★ 26.34 | 11.39 |
| 52 Week Low | $23.23 | $43.75 |
| 52 Week High | $49.09 | $57.17 |
Technical Indicators
Market Signals| Indicator | COLL | HTO |
|---|---|---|
| Relative Strength Index (RSI) | 68.88 | 46.89 |
| Support Level | $46.81 | $46.32 |
| Resistance Level | $49.09 | $48.42 |
| Average True Range (ATR) | 1.33 | 1.20 |
| MACD | -0.19 | 0.19 |
| Stochastic Oscillator | 69.59 | 60.28 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About HTO H2O America Common Stock
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come.